No Data
Sansure Biotech Inc. achieved a record high in net profit after deducting non-recurring items in 2024, but the gross margin of diagnostic instruments saw a significant decline.
① The company achieved a revenue of 1.458 billion yuan for the year, a year-on-year increase of 44.78%; the net income excluding non-recurring items was 0.202 billion yuan, a significant year-on-year increase of 182.25%; the net income attributable to the parent company was 0.276 billion yuan, a year-on-year decrease of 24.23%; ② Revenue from diagnostic instruments has significantly declined, with a gross margin that is negative, mainly due to intensified market competition and rising costs.
Sansure Biotech Inc. (688289.SH) reported a net income of 91.7355 million yuan in the first quarter, an increase of 13.22% year-on-year.
Gelonghui, April 29丨Sansure Biotech Inc. (688289.SH) released its quarterly report, achieving a total operating income of 0.475 billion yuan in the first quarter of 2025, a year-on-year increase of 21.62%; net income attributable to shareholders of the parent company was 91.7355 million yuan, an increase of 13.22% year-on-year; EPS was 0.16 yuan.
Sansure Biotech Inc.'s (SHSE:688289) Largest Shareholder, CEO Lizhong Dai Sees Holdings Value Fall by 3.9% Following Recent Drop
Shengxiang Biology: Shengxiang Biotechnology Co., Ltd. Report for the first quarter of 2025
Shengxiang Biology: Full text of the 2024 Annual Report of Shengxiang Biotechnology Co., Ltd.
Shengxiang Biology: Summary of the 2024 Annual Report of Shengxiang Biotechnology Co., Ltd.
